Turgut Bora Cengiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Turgut Bora Cengiz has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Afag Aghayeva
Department of General Surgery, Acibadem University, Acibadem Altunizade Hospital, Istanbul, Turkey
2 shared publications - Bilgi Baca
Department of General Surgery, Acibadem University, Acibadem Altunizade Hospital, Istanbul, Turkey
2 shared publications - Deniz Atasoy
Department of General Surgery, Acıbadem University School of Medicine, İstanbul, Turkey
2 shared publications Munir Ghesani
Division of Nuclear Medicine, Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
2 shared publications- Onur Bayraktar
Department of General Surgery, Acibadem University, Atakent Hospital, Istanbul, Turkey
2 shared publications Raksha Kulkarni
Department of Nuclear Medicine, Mount Sinai Hospital at Icahn School of Medicine, New York, NY, United States
2 shared publications
Latest Publications
- Open Access
- 15 March 2026
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 18
Synergy of PET and MR imaging in the local and regional staging of bladder cancer
The prognosis and optimal management of bladder cancer are closely dependent on accurate clinical staging. Traditional staging has relied on transurethral resection for T-staging in combination with cross-sectional imaging for N and M-staging. Computed tomography (CT) is the most accessible and common cross-sectional imaging modality to assess for local and distant spread of disease. However, CT alone lacks the contrast resolution to distinguish between non-muscle-invasive and muscle-invasive disease and has known difficulty distinguishing metastatic from normal lymph nodes (LNs). Magnetic resonance imaging (MRI) and positron emission tomography (PET) have been increasingly used in the workup of bladder cancer to address the shortcomings of CT imaging. MRI using the multiparametric combination of T2-weighted, dynamic contrast-enhanced, and diffusion-weighted imaging can more clearly delineate the extent of tumor involvement in the bladder. PET can use a variety of metabolically active radiotracers to visualize cancerous tissue, allowing the identification of metastases that may not be readily visible on CT. PET scans can also detect disease in normally sized LNs that do not meet conventional CT size thresholds. The combination of MRI and PET scans has not been explored in detail with respect to bladder cancer workup but may theoretically combine the strengths of both approaches to provide the most comprehensive, noninvasive tool for preoperative staging, with improved sensitivity and accuracy compared to other modalities. This narrative review uses a systematic search of the PubMed database from 2000 to 2025 to analyze MRI and PET, both separately and in synergy, for the local and distant staging of bladder cancer, as well as key technical advancements in these imaging technologies. Synergy of the imaging modalities potentially increases efficacy in bladder cancer staging.
- 15 March 2026
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 18
Open AccessSynergy of PET and MR imaging in the local and regional staging of bladder cancer
The prognosis and optimal management of bladder cancer are closely dependent on accurate clinical staging. Traditional staging has relied on transurethral resection for T-staging in combination with cross-sectional imaging for N and M-staging. Computed tomography (CT) is the most accessible and common cross-sectional imaging modality to assess for local and distant spread of disease. However, CT alone lacks the contrast resolution to distinguish between non-muscle-invasive and muscle-invasive disease and has known difficulty distinguishing metastatic from normal lymph nodes (LNs). Magnetic resonance imaging (MRI) and positron emission tomography (PET) have been increasingly used in the workup of bladder cancer to address the shortcomings of CT imaging. MRI using the multiparametric combination of T2-weighted, dynamic contrast-enhanced, and diffusion-weighted imaging can more clearly delineate the extent of tumor involvement in the bladder. PET can use a variety of metabolically active radiotracers to visualize cancerous tissue, allowing the identification of metastases that may not be readily visible on CT. PET scans can also detect disease in normally sized LNs that do not meet conventional CT size thresholds. The combination of MRI and PET scans has not been explored in detail with respect to bladder cancer workup but may theoretically combine the strengths of both approaches to provide the most comprehensive, noninvasive tool for preoperative staging, with improved sensitivity and accuracy compared to other modalities. This narrative review uses a systematic search of the PubMed database from 2000 to 2025 to analyze MRI and PET, both separately and in synergy, for the local and distant staging of bladder cancer, as well as key technical advancements in these imaging technologies. Synergy of the imaging modalities potentially increases efficacy in bladder cancer staging.
- Open Access
- 1 August 2025
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 34 (3) , 228-230
The Role of Bone Scintigraphy in Detection of Disseminated Coccidioides Fungemia
The Role of Bone Scintigraphy in Detection of Disseminated Coccidioides Fungemia - Molecular Imaging and Radionuclide Therapy
- 1 August 2025
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 34 (3) , 228-230
Open AccessThe Role of Bone Scintigraphy in Detection of Disseminated Coccidioides Fungemia
The Role of Bone Scintigraphy in Detection of Disseminated Coccidioides Fungemia - Molecular Imaging and Radionuclide Therapy
- Open Access
- 8 January 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1432758
Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs (VIPomas) not responsive to any other therapies who achieved symptomatic control and a significant decrease in serum VIP levels with PRRT during their hospital stay. Two patients with VIPomas were admitted to the hospital with multiple prior hospital admissions after going through multiple lines of therapy. The first patient was a 47-year-old woman with a grade 2 pancreatic VIP-secreting NET. She was treated with somatostatin analogs and chemotherapy; however, she experienced recurrent symptoms and complications leading to two hospital admissions, one of which included an intensive care unit (ICU) admission. The patient was treated with lutetium-177 DOTATATE while in the hospital, which led to the resolution of the symptoms and a marked decline in serum VIP levels, and she was able to be discharged from the hospital after 147 days of hospitalization (16 days after PRRT). The second patient was a 27-year-old man who was diagnosed with a well-differentiated grade 3 pancreatic VIPoma. He also suffered from severe diarrhea and was not responsive to any form of therapy, including liver embolization. He was also treated with PRRT on admission, which led to immediate resolution of his symptoms and a decrease in tumor markers. In conclusion, 177Lu-DOTATATE is an effective treatment for highly symptomatic VIPoma. Inpatient administration of PRRT can rapidly reduce diarrhea and fluid and electrolyte complications of VIP secretion and may shorten hospital stays.
- 8 January 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1432758
Open AccessCase report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs (VIPomas) not responsive to any other therapies who achieved symptomatic control and a significant decrease in serum VIP levels with PRRT during their hospital stay. Two patients with VIPomas were admitted to the hospital with multiple prior hospital admissions after going through multiple lines of therapy. The first patient was a 47-year-old woman with a grade 2 pancreatic VIP-secreting NET. She was treated with somatostatin analogs and chemotherapy; however, she experienced recurrent symptoms and complications leading to two hospital admissions, one of which included an intensive care unit (ICU) admission. The patient was treated with lutetium-177 DOTATATE while in the hospital, which led to the resolution of the symptoms and a marked decline in serum VIP levels, and she was able to be discharged from the hospital after 147 days of hospitalization (16 days after PRRT). The second patient was a 27-year-old man who was diagnosed with a well-differentiated grade 3 pancreatic VIPoma. He also suffered from severe diarrhea and was not responsive to any form of therapy, including liver embolization. He was also treated with PRRT on admission, which led to immediate resolution of his symptoms and a decrease in tumor markers. In conclusion, 177Lu-DOTATATE is an effective treatment for highly symptomatic VIPoma. Inpatient administration of PRRT can rapidly reduce diarrhea and fluid and electrolyte complications of VIP secretion and may shorten hospital stays.
- Open Access
- 28 September 2024
- Published by MDPI AG in Journal of Imaging
- Vol. 10 (10) , 244
Radiological Diagnosis and Advances in Imaging of Vertebral Compression Fractures
Vertebral compression fractures (VCFs) affect 1.4 million patients every year, especially among the globally aging population, leading to increased morbidity and mortality. Often characterized with symptoms of sudden onset back pain, decreased vertebral height, progressive kyphosis, and limited mobility, VCFs can significantly impact a patient’s quality of life and are a significant public health concern. Imaging modalities in radiology, including radiographs, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) studies and bone scans, play crucial and evolving roles in the diagnosis, assessment, and management of VCFs. An understanding of anatomy, and the extent to which each imaging modality serves to elucidate that anatomy, is crucial in understanding and providing guidance on fracture severity, classification, associated soft tissue injuries, underlying pathologies, and bone mineral density, ultimately guiding treatment decisions, monitoring treatment response, and predicting prognosis and long-term outcomes. This article thus explores the important role of radiology in illuminating the underlying anatomy and pathophysiology, classification, diagnosis, treatment, and management of patients with VCFs. Continued research and advancements in imaging technologies will further enhance our understanding of VCFs and pave the way for personalized and effective management strategies.
- 28 September 2024
- Published by MDPI AG in Journal of Imaging
- Vol. 10 (10) , 244
Open AccessRadiological Diagnosis and Advances in Imaging of Vertebral Compression Fractures
Vertebral compression fractures (VCFs) affect 1.4 million patients every year, especially among the globally aging population, leading to increased morbidity and mortality. Often characterized with symptoms of sudden onset back pain, decreased vertebral height, progressive kyphosis, and limited mobility, VCFs can significantly impact a patient’s quality of life and are a significant public health concern. Imaging modalities in radiology, including radiographs, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) studies and bone scans, play crucial and evolving roles in the diagnosis, assessment, and management of VCFs. An understanding of anatomy, and the extent to which each imaging modality serves to elucidate that anatomy, is crucial in understanding and providing guidance on fracture severity, classification, associated soft tissue injuries, underlying pathologies, and bone mineral density, ultimately guiding treatment decisions, monitoring treatment response, and predicting prognosis and long-term outcomes. This article thus explores the important role of radiology in illuminating the underlying anatomy and pathophysiology, classification, diagnosis, treatment, and management of patients with VCFs. Continued research and advancements in imaging technologies will further enhance our understanding of VCFs and pave the way for personalized and effective management strategies.
- 16 May 2024
- Published by SAGE Publications in Urologia Journal
- Vol. 91 (3) , 525-530
Does enzalutamide related PSMA upregulation affect outcomes of lutetium-177 PSMA radioligand therapy?
Background: Enzalutamide is an antiandrogen drug used prior to lutetium-177 prostate specific membrane antigen (Lu-PSMA) radioligand therapy and has shown promising results for upregulating the PSMA expression on prostate cancer cells. In this study, we aim to compare prostate specific antigen (PSA) level changes in prostate cancer patients who received enzalutamide to those who did not. Methods: Prostate cancer patients who underwent Lu-PSMA between 2021 and 2023 were retrospectively included. Patients were grouped based on prior enzalutamide therapy: those who received enzalutamide (EZ+) for at least 14 days and those who did not (EZ−). PSA changes and F-18 DCFPyL SUV (Standardized Uptake Values) were compared. Results: Thirty-seven patients were included, 18 EZ+ and 19 EZ−. The median age, Gleason score, and prior chemo/hormonal therapies were similar for EZ+ and EZ−, except for radium-223. Eleven patients (61%) in EZ+ and 13 patients (68%) in EZ− showed a decrease in PSA after the first cycle ( p = 0.64). Four patients (22%) in EZ+ and seven patients (37%) in EZ− had more than 50% decrease in PSA after the first cycle ( p = 0.33). The average percent decline at the end of the treatment was 23.3% in EZ+ and 50.4% in EZ− ( p = 0.4). There was no difference in terms of lesion with highest SUVmax, mean SUV, total tumor volume or activity on pre-therapy PSMA imaging. Conclusion: Enzalutamide treatment prior to Lu-PSMA does not improve patient outcomes when applied remotely. Larger studies evaluating the combination therapies and the timing of enzalutamide are needed to assess its correlation with Lu-PSMA outcomes.
- 16 May 2024
- Published by SAGE Publications in Urologia Journal
- Vol. 91 (3) , 525-530
Does enzalutamide related PSMA upregulation affect outcomes of lutetium-177 PSMA radioligand therapy?
Background: Enzalutamide is an antiandrogen drug used prior to lutetium-177 prostate specific membrane antigen (Lu-PSMA) radioligand therapy and has shown promising results for upregulating the PSMA expression on prostate cancer cells. In this study, we aim to compare prostate specific antigen (PSA) level changes in prostate cancer patients who received enzalutamide to those who did not. Methods: Prostate cancer patients who underwent Lu-PSMA between 2021 and 2023 were retrospectively included. Patients were grouped based on prior enzalutamide therapy: those who received enzalutamide (EZ+) for at least 14 days and those who did not (EZ−). PSA changes and F-18 DCFPyL SUV (Standardized Uptake Values) were compared. Results: Thirty-seven patients were included, 18 EZ+ and 19 EZ−. The median age, Gleason score, and prior chemo/hormonal therapies were similar for EZ+ and EZ−, except for radium-223. Eleven patients (61%) in EZ+ and 13 patients (68%) in EZ− showed a decrease in PSA after the first cycle ( p = 0.64). Four patients (22%) in EZ+ and seven patients (37%) in EZ− had more than 50% decrease in PSA after the first cycle ( p = 0.33). The average percent decline at the end of the treatment was 23.3% in EZ+ and 50.4% in EZ− ( p = 0.4). There was no difference in terms of lesion with highest SUVmax, mean SUV, total tumor volume or activity on pre-therapy PSMA imaging. Conclusion: Enzalutamide treatment prior to Lu-PSMA does not improve patient outcomes when applied remotely. Larger studies evaluating the combination therapies and the timing of enzalutamide are needed to assess its correlation with Lu-PSMA outcomes.
- Open Access
- 16 May 2023
- Published by Medknow in Annals of Thoracic Medicine
- Vol. 18 (4) , 199-205
The diagnostic accuracy of perfusion-only scan in the diagnosis of pulmonary embolism in the era of COVID-19: A single-center study of 434 patients
INTRODUCTION: There is a paucity of data in the literature regarding the diagnostic accuracy of perfusion (Q)-only studies in the absence of ventilation images. This study aims to assess the diagnostic accuracy of Q-only imaging in the pandemic era. METHODS: Patients who underwent Q-only imaging for pulmonary embolism between March 2020 and February 2021 were analyzed. Patients who underwent lung quantification analysis were excluded. Q-only test results were reported as per modified PIOPED II criteria and single positron emission tomography/computed tomography (SPECT/CT) imaging was performed as needed. Patients were considered concordant or discordant by correlating the Q-only results with CT angiogram (CTA) or clinical diagnosis made through chart review. The diagnostic accuracy was calculated after excluding intermediate probability and nondiagnostic studies. RESULTS: Four hundred and thirty-four patients were identified. One hundred and twenty-eight patients (29.4%) underwent ultrasound Doppler, 37 patients (8.5%) underwent CTA, and 16 patients (3.6%) underwent both. After excluding patients with intermediate probability or nondiagnostic studies and who did not have follow-up (a total of 87 patients [20%]), 347 patients were enrolled in the final analysis. The combined planar and SPECT/CT sensitivity and specificity were 85.4% (72.2%–93.9% confidence interval [CI]) and 98.7% (96.9%–98.6% CI), respectively. The positive predictive value (PPV) of the Q-only imaging was 89.1% (77.3%–95.1% CI) and the negative predictive value (NPV) was 98.2% (96.4%–99% CI). The sensitivity with SPECT/CT reached 100% (CI: 71.5%–100%) with a specificity of 92.3% (CI: 64%–99.8%). The PPV was 85.7% (CI: 62.1%–95.6%) and the NPV was 100%. CONCLUSION: Q-only imaging provides clinically acceptable results. The sensitivity of the Q-only scan is increased when coupled with SPECT/CT.
- 16 May 2023
- Published by Medknow in Annals of Thoracic Medicine
- Vol. 18 (4) , 199-205
Open AccessThe diagnostic accuracy of perfusion-only scan in the diagnosis of pulmonary embolism in the era of COVID-19: A single-center study of 434 patients
INTRODUCTION: There is a paucity of data in the literature regarding the diagnostic accuracy of perfusion (Q)-only studies in the absence of ventilation images. This study aims to assess the diagnostic accuracy of Q-only imaging in the pandemic era. METHODS: Patients who underwent Q-only imaging for pulmonary embolism between March 2020 and February 2021 were analyzed. Patients who underwent lung quantification analysis were excluded. Q-only test results were reported as per modified PIOPED II criteria and single positron emission tomography/computed tomography (SPECT/CT) imaging was performed as needed. Patients were considered concordant or discordant by correlating the Q-only results with CT angiogram (CTA) or clinical diagnosis made through chart review. The diagnostic accuracy was calculated after excluding intermediate probability and nondiagnostic studies. RESULTS: Four hundred and thirty-four patients were identified. One hundred and twenty-eight patients (29.4%) underwent ultrasound Doppler, 37 patients (8.5%) underwent CTA, and 16 patients (3.6%) underwent both. After excluding patients with intermediate probability or nondiagnostic studies and who did not have follow-up (a total of 87 patients [20%]), 347 patients were enrolled in the final analysis. The combined planar and SPECT/CT sensitivity and specificity were 85.4% (72.2%–93.9% confidence interval [CI]) and 98.7% (96.9%–98.6% CI), respectively. The positive predictive value (PPV) of the Q-only imaging was 89.1% (77.3%–95.1% CI) and the negative predictive value (NPV) was 98.2% (96.4%–99% CI). The sensitivity with SPECT/CT reached 100% (CI: 71.5%–100%) with a specificity of 92.3% (CI: 64%–99.8%). The PPV was 85.7% (CI: 62.1%–95.6%) and the NPV was 100%. CONCLUSION: Q-only imaging provides clinically acceptable results. The sensitivity of the Q-only scan is increased when coupled with SPECT/CT.
- 13 September 2021
- Published by Wiley in The International Journal of Medical Robotics and Computer Assisted Surgery
- Vol. 17 (6) , e2331
Cost‐conscious robotic restorative proctectomy has similar economic and oncologic outcomes to open restorative proctectomy: Results of a long‐term follow‐up study
Background: In this study, we hypothesised that the direct hospital costs of robotic restorative proctectomy (RP) would be similar to those of open RP when a cost‐conscious approach was employed in rectal cancer patients.Methods: We included consecutive patients with rectal cancer who underwent RP between 12/2011 and 10/2014. A cost‐conscious approach was employed in robotic surgery. We compared demographics, long‐term oncologic outcomes, and direct hospital costs between the open and robotic groups.Results: There were 32 robotic and 68 open RP procedures performed. Compared to open RP, the robotic RP group had a longer operative time but less estimated blood loss, intraoperative transfusions, overall short‐term morbidity, decreased length of stay. After the initial five robotic cases, overall hospital costs were comparable between the groups (1 ± 0.5 vs. 1 ± 0.4, open and robotic RP, respectively, p = 0.90).Conclusion: Increasing surgeon experience and a cost‐conscious approach may improve the value of care of robotic RP in patients with rectal cancer.
- 13 September 2021
- Published by Wiley in The International Journal of Medical Robotics and Computer Assisted Surgery
- Vol. 17 (6) , e2331
Cost‐conscious robotic restorative proctectomy has similar economic and oncologic outcomes to open restorative proctectomy: Results of a long‐term follow‐up study
Background: In this study, we hypothesised that the direct hospital costs of robotic restorative proctectomy (RP) would be similar to those of open RP when a cost‐conscious approach was employed in rectal cancer patients.Methods: We included consecutive patients with rectal cancer who underwent RP between 12/2011 and 10/2014. A cost‐conscious approach was employed in robotic surgery. We compared demographics, long‐term oncologic outcomes, and direct hospital costs between the open and robotic groups.Results: There were 32 robotic and 68 open RP procedures performed. Compared to open RP, the robotic RP group had a longer operative time but less estimated blood loss, intraoperative transfusions, overall short‐term morbidity, decreased length of stay. After the initial five robotic cases, overall hospital costs were comparable between the groups (1 ± 0.5 vs. 1 ± 0.4, open and robotic RP, respectively, p = 0.90).Conclusion: Increasing surgeon experience and a cost‐conscious approach may improve the value of care of robotic RP in patients with rectal cancer.
- 10 August 2020
- Published by Wiley in Journal of Surgical Oncology
- Vol. 122 (6) , 1132-1144
Survival outcomes after surgical management of sporadic or familial adenomatous polyposis associated duodenal cancer
Background: Duodenal cancer is the second most common cause of cancer death in familial adenomatous polyposis (FAP) patients. In this study, we compare oncologic outcomes between sporadic and FAP‐associated duodenal cancer.Methods: In this retrospective study, all patients who underwent surgeries between 2000 and 2014 for either sporadic or FAP duodenal cancer were identified. The patients were grouped based on diagnoses and perioperative and survival outcomes were compared.Results: A total of 56 patients with duodenal cancer (43 sporadic, 13 FAP) who underwent surgery were identified. Pancreatoduodenectomy (PD) was the most common procedure performed. The overall median survival was 7.5 years (1 year: 92%; 5 years: 58.1%). FAP patients had earlier tumor, node, and metastasis stage, less margin involvement, less perineural, and angiolymphatic invasion but had a comparable survival to sporadic patients. The median survival for FAP duodenal cancer was 7.4 vs 9.6 years for sporadic (P = .97) with similar utilization of adjuvant chemotherapy. Although not statistically significant, PD had an improved median survival compared to segmental duodenal resection (SDR) (9.6 years for PD vs 3.6 years for SDR, P = .17). Non‐periampullary location and presence of positive lymph nodes were significant predictors of mortality on multivariate analysis.Conclusions: FAP duodenal cancer has no survival advantage compared to sporadic duodenal cancer despite an improved stage of resection with extraampullary lesions having a worse survival.
- 10 August 2020
- Published by Wiley in Journal of Surgical Oncology
- Vol. 122 (6) , 1132-1144
Survival outcomes after surgical management of sporadic or familial adenomatous polyposis associated duodenal cancer
Background: Duodenal cancer is the second most common cause of cancer death in familial adenomatous polyposis (FAP) patients. In this study, we compare oncologic outcomes between sporadic and FAP‐associated duodenal cancer.Methods: In this retrospective study, all patients who underwent surgeries between 2000 and 2014 for either sporadic or FAP duodenal cancer were identified. The patients were grouped based on diagnoses and perioperative and survival outcomes were compared.Results: A total of 56 patients with duodenal cancer (43 sporadic, 13 FAP) who underwent surgery were identified. Pancreatoduodenectomy (PD) was the most common procedure performed. The overall median survival was 7.5 years (1 year: 92%; 5 years: 58.1%). FAP patients had earlier tumor, node, and metastasis stage, less margin involvement, less perineural, and angiolymphatic invasion but had a comparable survival to sporadic patients. The median survival for FAP duodenal cancer was 7.4 vs 9.6 years for sporadic (P = .97) with similar utilization of adjuvant chemotherapy. Although not statistically significant, PD had an improved median survival compared to segmental duodenal resection (SDR) (9.6 years for PD vs 3.6 years for SDR, P = .17). Non‐periampullary location and presence of positive lymph nodes were significant predictors of mortality on multivariate analysis.Conclusions: FAP duodenal cancer has no survival advantage compared to sporadic duodenal cancer despite an improved stage of resection with extraampullary lesions having a worse survival.
- Open Access
- 28 September 2018
- Published by Galenos Yayinevi in Turkish Journal of Surgery
- Vol. 34 (3) , 217-220
Effects of prior abdominal surgery on laparoscopic cholecystectomy
With increased experience and technological advancement, laparoscopic cholecystectomy is reported to be safe and feasible even in the presence of most of the previously recognized contraindications. The purpose of this study was to explore the effects of prior upper and lower abdominal surgery on laparoscopic cholecystectomy. A retrospective evaluation of all sequential patients who underwent laparoscopic cholecystectomy from January 2014 to June 2016 was conducted. Patients were divided into three groups (Group A: patients without any prior abdominal surgical procedures; Group B: patients with prior upper abdominal surgical procedures; and Group C: patients with prior lower abdominal surgical procedures). A total of 329 patients were assessed. Group A consisted of 223, Group B of 18, and Group C of 88 patients. A statistically significantly higher operative time, postoperative pain, and complication rate after laparoscopic cholecystectomy were noted in patients with prior upper abdominal surgery. The groups were comparable regarding patients' demographics and surgery indications. The length of hospital stay was not statistically different between the groups (p=0.065). According to the results of the current study, prior upper abdominal surgery leads to a significantly longer procedure time, higher postoperative pain, and complication rates after laparoscopic cholecystectomy. However, the length of hospital stay was not affected by the parameters investigated.
- 28 September 2018
- Published by Galenos Yayinevi in Turkish Journal of Surgery
- Vol. 34 (3) , 217-220
Open AccessEffects of prior abdominal surgery on laparoscopic cholecystectomy
With increased experience and technological advancement, laparoscopic cholecystectomy is reported to be safe and feasible even in the presence of most of the previously recognized contraindications. The purpose of this study was to explore the effects of prior upper and lower abdominal surgery on laparoscopic cholecystectomy. A retrospective evaluation of all sequential patients who underwent laparoscopic cholecystectomy from January 2014 to June 2016 was conducted. Patients were divided into three groups (Group A: patients without any prior abdominal surgical procedures; Group B: patients with prior upper abdominal surgical procedures; and Group C: patients with prior lower abdominal surgical procedures). A total of 329 patients were assessed. Group A consisted of 223, Group B of 18, and Group C of 88 patients. A statistically significantly higher operative time, postoperative pain, and complication rate after laparoscopic cholecystectomy were noted in patients with prior upper abdominal surgery. The groups were comparable regarding patients' demographics and surgery indications. The length of hospital stay was not statistically different between the groups (p=0.065). According to the results of the current study, prior upper abdominal surgery leads to a significantly longer procedure time, higher postoperative pain, and complication rates after laparoscopic cholecystectomy. However, the length of hospital stay was not affected by the parameters investigated.
- 2 August 2017
- Published by Wiley in Colorectal Disease
- Vol. 19 (8) , 786
Robotic TAPP repair of incarcerated femoral hernia with utilization of indocyanine green dye – a video vignette
- 2 August 2017
- Published by Wiley in Colorectal Disease
- Vol. 19 (8) , 786
Robotic TAPP repair of incarcerated femoral hernia with utilization of indocyanine green dye – a video vignette